Biogen Gives Up On Gosuranemab After No Benefit Seen In Alzheimer's Study

Phase II TANGO Trial Was Targeting Anti-Tau For Early Disease

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.